Somewhere in a federal filing cabinet sat a document the public wasn't supposed to see for a long time. It took two Freedom of Information Act requests and the better part of two years before the DEA finally handed it over — a report titled Ayahuasca: Risks to Public Health and Safety, dated July 2020. Once it surfaced, the scientific community read it, raised eyebrows, and then sharpened their pens.

If you're researching ayahuasca seriously — maybe weighing a retreat in Peru, maybe wondering whether the legal grey zone in the U.S. is shifting — this story matters. It tells you a lot about why ayahuasca occupies the strange position it does in American law, why research has been so slow despite mounting evidence of therapeutic benefit, and why the regulatory landscape isn't likely to shift overnight. Knowing this context changes how you think about plant medicine, about master plants, and about the whole machinery surrounding psychedelics and addiction recovery in the West.

What the DEA Report Actually Said

The report came out of an internal DEA review and landed firmly on the prohibitionist side of the ledger. Its core claim: ayahuasca poses a meaningful risk to public health and safety. That framing matters because it props up the federal classification of DMT — the active alkaloid in the brew — as a Schedule I substance. Schedule I, in DEA parlance, means a drug with high abuse potential and no accepted medical use. The agency has long argued that ayahuasca is essentially a delivery vehicle for DMT, which is how it justifies the same legal treatment.

The trouble is, the report leaned heavily on a curated stack of references that supported its conclusions while leaving out a striking amount of contrary evidence. There was no mention, for instance, of the first randomized controlled trial of ayahuasca for treatment-resistant depression — a study that suggested both reasonable tolerability and meaningful clinical benefit. There was scant engagement with decades of epidemiological data from Indigenous Amazonian communities and the Brazilian religious churches (Santo Daime, União do Vegetal) where ayahuasca has been consumed ceremonially for generations without the public-health catastrophe the agency seems to anticipate.

In other words: the science was selective. Not absent, just trimmed.

The Peer-Reviewed Rebuttal

In June 2023, the Chacruna Institute — together with scholars across biology, neuroscience, psychiatry, anthropology, and sociology — published a formal critique in the Journal of Psychedelic Studies. The article walked through the DEA report point by point, documenting factual omissions, theoretical assumptions presented as established fact, and what looked an awful lot like confirmation bias dressed up in citations.

A few of the rebuttal's sharpest threads:

• The report's literature review wasn't systematic. A proper review surveys the field; this one cherry-picked.
• Risk data from Indigenous and ceremonial settings — where ayahuasca has been used safely at scale for centuries — was either ignored or treated as anecdotal.
• Clinical trial data showing antidepressant and anti-addictive potential got short shrift or no mention at all.
• The agency conflated ayahuasca with synthesized DMT, despite pharmacological differences in how the brew is metabolized (the MAOI component in the vine fundamentally changes the experience and duration).

The point of the critique wasn't to declare ayahuasca a miracle cure. It was to insist that policy this consequential should rest on a complete reading of the evidence, not a partial one.

Why This Matters If You're Considering a Retreat

Here's where the abstract policy fight touches the ground. If you're a person in the U.S. researching ayahuasca because nothing else has worked for your depression, your drinking, your PTSD — the federal stance on plant medicine is a big part of why you're probably looking at a retreat in Peru, Costa Rica, or Brazil rather than a clinic in Colorado.

The Schedule I classification creates real downstream effects. Research funding is harder to secure. Clinical trials face procedural hurdles that drugs in other categories don't. Therapists who might otherwise help with integration work risk their licenses if they get too close to the substance itself. And practitioners who run ceremonies in the U.S. — outside the narrow religious exemptions granted to the UDV in 2006 and to Santo Daime shortly after — operate in legal jeopardy.

That's the landscape you're navigating when you start comparing retreat centers. The retreat industry that's grown up in Latin America exists in part because of these federal blockages. Many facilitators are themselves U.S. expats who relocated precisely because they couldn't practice openly at home.

The Bigger Question: Is the DEA Likely to Change Course?

Short answer: not soon. The agency's mandate is enforcement, not research advocacy. Drug scheduling decisions technically flow from a coordinated process involving the FDA, but the DEA has historically resisted descheduling petitions even when the underlying science had moved on. The most-cited example is cannabis — twenty-five-plus years of state-level legalization, mounting clinical data, and federal scheduling has barely budged.

A few realistic paths forward, in rough order of likelihood:

1. FDA approval of a psychedelic-assisted therapy. If psilocybin or MDMA gets approved for a clinical indication, the DEA would have to reschedule that specific compound. This would set precedent but wouldn't automatically extend to ayahuasca.
2. Religious freedom litigation. Groups like the Church of the Eagle and the Condor have won exemptions before. Each successful case chips at the edges of prohibition without changing the schedule itself.
3. Congressional intervention. Possible but politically heavy. Lawmakers haven't done it for cannabis; they're unlikely to lead with ayahuasca.
4. State-level decriminalization. Several jurisdictions have already moved on entheogenic plants. This doesn't change federal law but it shifts the cultural baseline.

For now, the gap between what the research suggests about plant medicine and addiction recovery — and what U.S. policy permits — remains wide. The Chacruna rebuttal won't close it by itself, but it's the kind of scholarship that eventually changes minds in the rooms where these decisions get made.

What This Means for the Way You Choose a Retreat

If you've read this far, you're the kind of person who wants to make an informed decision rather than just chase a transformative-sounding weekend. A few honest pointers, born out of the policy reality above:

• Legal status varies wildly by country. Peru and Brazil have explicit protections for traditional ayahuasca use. Costa Rica operates in a tolerant grey zone. The U.S. and most of Europe do not. Know where you're going and what rules apply.
• Reputable retreat centers care about screening. Ayahuasca interacts dangerously with SSRIs and certain other medications. A center that doesn't ask about your medical history is a center to avoid.
• Integration is where the actual healing happens. The ceremony is a few nights. The work of translating what you experienced into changed behavior takes months. Ask any retreat what they offer post-ceremony.
• Be skeptical of guarantees. Anyone promising you'll be cured of addiction, depression, or trauma in a week is selling, not facilitating. The research suggests potential — not certainty.
• Cultural respect matters. The traditions you're drawing on belong to people. The best centers acknowledge that lineage rather than packaging it as an exotic backdrop.

The DEA's report tried to flatten a complex picture into a single warning label. The peer-reviewed response did the harder work of holding multiple truths at once: yes, there are risks; yes, there is therapeutic promise; yes, the science deserves better than selective citation. That's the spirit you want to bring to your own research, too.

If something in this piece resonates and you're ready to look at the practical side of things, a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — the medicine isn't going anywhere, and the right setting matters more than the calendar does.